"Tobramycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.
Descriptor ID |
D014031
|
MeSH Number(s) |
D09.408.051.476.600.800
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tobramycin".
Below are MeSH descriptors whose meaning is more specific than "Tobramycin".
This graph shows the total number of publications written about "Tobramycin" by people in this website by year, and whether "Tobramycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2002 | 1 | 2 | 3 |
2003 | 0 | 1 | 1 |
2004 | 1 | 1 | 2 |
2007 | 1 | 0 | 1 |
2010 | 1 | 2 | 3 |
2011 | 1 | 1 | 2 |
2012 | 2 | 0 | 2 |
2015 | 2 | 0 | 2 |
2016 | 2 | 2 | 4 |
2017 | 0 | 1 | 1 |
2018 | 0 | 1 | 1 |
2019 | 1 | 1 | 2 |
2020 | 1 | 0 | 1 |
2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tobramycin" by people in Profiles.
-
Bassenden AV, Dumalo L, Park J, Blanchet J, Maiti K, Arya DP, Berghuis AM. Structural and phylogenetic analyses of resistance to next-generation aminoglycosides conferred by AAC(2') enzymes. Sci Rep. 2021 06 02; 11(1):11614.
-
Harruff EE, Kil J, Ortiz MGT, Dorgan D, Jain R, Poth EA, Fifer RC, Kim YJM, Shoup AG, Flume PA. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment. J Cyst Fibros. 2021 03; 20(2):288-294.
-
Kirby BD, Al Ahmar R, Withers TR, Valentine ME, Valentovic M, Long TE, Gaskins JR, Yu HD. Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice. Antimicrob Agents Chemother. 2019 07; 63(7).
-
Lewin JJ, Cook AM, Gonzales C, Merola D, Neyens R, Peppard WJ, Brophy GM, Kurczewski L, Giarratano M, Makii J, Rowe AS, Tesoro EP, Zaniewski A, Clark S, Ziai WC. Current Practices of Intraventricular Antibiotic Therapy in the Treatment of Meningitis and Ventriculitis: Results from a Multicenter Retrospective Cohort Study. Neurocrit Care. 2019 06; 30(3):609-616.
-
Garcia BA, Carden JL, Goodwin DL, Smith TA, Gaggar A, Leon K, Antony VB, Rowe SM, Solomon GM. Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients. BMC Pulm Med. 2018 Feb 14; 18(1):35.
-
Bury PDS, Huang F, Li S, Sun Y, Leadlay PF, Dias MVB. Structural Basis of the Selectivity of GenN, an Aminoglycoside N-Methyltransferase Involved in Gentamicin Biosynthesis. ACS Chem Biol. 2017 11 17; 12(11):2779-2787.
-
Ereshefsky BJ, Al-Hasan MN, Gokun Y, Martin CA. Comparison of ß-lactam plus aminoglycoside versus ß-lactam plus fluoroquinolone empirical therapy in serious nosocomial infections due to Gram-negative bacilli. J Chemother. 2017 Feb; 29(1):30-37.
-
Flume PA, Clancy JP, Retsch-Bogart GZ, Tullis DE, Bresnik M, Derchak PA, Lewis SA, Ramsey BW. Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):809-815.
-
Niepa TH, Wang H, Dabrowiak JC, Gilbert JL, Ren D. Synergy between tobramycin and trivalent chromium ion in electrochemical control of Pseudomonas aeruginosa. Acta Biomater. 2016 05; 36:286-95.
-
Elborn JS, Flume PA, Cohen F, Loutit J, VanDevanter DR. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. J Cyst Fibros. 2016 09; 15(5):634-40.